After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited ... with a chance of $1 billion-plus sales at peak.

US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche ... from the University of Massachusetts Medical School, Atalanta says it could change ...

Having witnessed a 90%-plus stock price slide during recent years, Sage Therapeutics’ leadership must decide whether now is the right time to accept a buyout offer. Biogen has offered to ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

They split research costs and, after the medicine got approved as a treatment for postpartum depression, began sharing profits. But Biogen now wants Zurzuvae all to itself. In a Jan. 10 letter to ...

SAN FRANCISCO Jan 14 (Reuters) - Biogen (BIIB.O), opens new tab expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business ...

Jan 10 (Reuters) - Drugmaker Biogen (BIIB.O), opens new tab will buy all outstanding shares of Sage Therapeutics (SAGE.O), opens new tab that it does not already own for $7.22 apiece, a filing ...